Nasdaq

Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies

SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Seeking Alpha

Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025

SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Nasdaq

Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.

SALT LAKE CITY, Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...
Morningstar

Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform

Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives SALT LAKE CITY, Nov. 3, 2025 /PRNewswire/ ...
Business Wire

Molecular Diagnostics at the Point of Care Market Research 2025-2029: New Genotypes Creating New Markets, Aging Population a Boon for All Diagnostics, Developing World Driving ...

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key ...
Business Wire

SYNAPS Dx Resolves Alzheimer’s Disease Diagnostic Dilemma: White Paper Documents Improved Diagnostic Pathway with Highly Accurate, Accessible Skin Test

ROCKVILLE, Md.--(BUSINESS WIRE)--SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to ...